The odds of an increase in regulation of the massive, and growing, sports-betting industry may be shifting.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
There were plenty of business losers in 2024, but only one for whom the sky was literally falling. In short: Boeing had a bad year.
Luxury brands were riding the subway instead of lounging in limos this year, though a couple of brands were able to buck the trend.
This year Big Tech got into the energy game in a big way, and if it wants to chase AI it’ll need even more energy in years to come.
Across-the-board inflation — including food costs, labor costs, and real estate costs — is pummeling restaurants. Can the industry survive?
YouTube may have started off as a platform for small screens, but now it’s increasingly dominating the living room TV.
In 2024, legacy media giants like Disney and NBCUniversal finally had enough with cable — and started making their own off-ramps.
For years, traditional cable had one trump card against the upstart streamers devouring their business: live programming. Not anymore.
Spurred by “the rise of Chinese power,” Japanese automakers Honda and Nissan announced Monday that they are in talks to merge.
The secret ingredients to Lego’s success? A clutch of licensing deals and finding ways to sell Lego sets to kids well over the age of 30.
Though small compared to each company’s total workforces, work stoppages have set uncomfortable precedents for management.
In the first 11 months of the year, 1,991 CEOs have announced their departures, up 16% compared to the same timeframe last year.
The offer would put an 83% premium on Soho’s Wednesday closing price and comes a year after it had to close off admissions in three cities.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.